Lower doses used during the titration phase (typically 0.25 mg to 0.5 mg weekly) often cost less than maintenance doses of 1 mg or 2.4 mg
A Nature Medicine review published in January 2026 described GLP-1 medicines as "being prescribed to growing numbers of patients worldwide" for an expanding list of indications and noted that "new, more effective molecules with optimised pharmacokinetics produce greater weight loss and some may be more effective for various metabolic disorders, through incorporation of one or more additional peptide epitopes." The clinical pipeline includes 39 GLP-1 receptor agonist drugs in development across 34 companies, with only seven coming from the top 20 pharmaceutical firms
Any clinical use of AOD 9604 today is off-label and falls under the supervision of a licensed provider using a compounded preparation
It can scavenge free radicals, inhibit ROS production, and modulate various signaling pathways involved in oxidative stress
However, as mentioned above, the data is mixed
Most patients notice reduced shedding and a healthier-looking scalp within 2 to 4 weeks